Latest News
-
Single shot breast cancer treatment approved
The hours that some patients spend receiving breast cancer chemotherapy in hospital is being reduced to five minutes, it has been announced. Read more
-
Perinatal mental health hubs announced
England is to get 26 hubs to provide support for mothers with mental health problems, it has been announced. Read more
-
Melanoma linked to high testosterone in men
There may be a link between high levels of testosterone in the blood and increased risk of melanoma in men, according to a new analysis. Read more
-
Hospitalised COVID-19 patients face organ damage risk
People discharged from hospital after being treated for COVID-19 are more likely to suffer from multi-organ dysfunction. Read more
-
New gene variant linked to infertility in men
Scientists have identified a new genetic variant they believe is linked to male infertility. Read more
-
Facemasks must continue after lockdown, urge scientists
The UK should continue to require the use of facemasks after other lockdown restrictions are ended, according to an analysis published today. Read more
-
Glaucoma type linked to cognitive impairment risk
Normal-tension glaucoma has been linked to an increased risk of cognitive impairment and possibly dementia, Australian researchers report today. Read more
-
Risks of exercising outside when air quality is poor
Young people should avoid very strenuous physical activity on days when air pollution levels are high, according to new research from South Korea published today. Read more
-
Asthma attacks reduced in first COVID-19 phase
Fewer than normal patients presented with severe asthma attacks, or were hospitalised with pneumonia, influenza and chronic lung diseases during the first phase of the COVID-19 pandemic, according to three new studies. Read more
-
Vaccine success evidence as lockdown eased
Vaccination is proving highly effective in preventing deaths and infection in the UK, according to a series of studies released as lockdown restrictions are relaxed in England. Read more
